BullFrog AI Holdings, Inc.
BFRG
查看详细走势图
1.130USD
+0.090+8.65%
收盘 12/19, 16:00（美东）报价延迟15分钟
11.77M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+8.65%
5天
+2.73%
1月
+29.86%
6月
-31.52%
今年开始到现在
-43.50%
1年
-45.93%
查看详细走势图
TradingKey BullFrog AI Holdings, Inc.股票评分
单位: USD 更新时间: 2025-12-19操作建议
BullFrog AI Holdings, Inc.当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名209/404位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
BullFrog AI Holdings, Inc.评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
--
目标均价
--
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
BullFrog AI Holdings, Inc.亮点
亮点风险
Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
BullFrog AI Holdings, Inc.新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
BullFrog AI Holdings, Inc.简介
Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.
公司代码BFRG
公司BullFrog AI Holdings, Inc.
CEOSingh (Vininder)
网址https://www.bullfrogai.com
常见问题
BullFrog AI Holdings, Inc.(BFRG)的当前股价是多少？
BullFrog AI Holdings, Inc.(BFRG)的当前股价是 1.130。
BullFrog AI Holdings, Inc.的股票代码是什么？
BullFrog AI Holdings, Inc.的股票代码是BFRG。
BullFrog AI Holdings, Inc.股票的52周最高点是多少？
BullFrog AI Holdings, Inc.股票的52周最高点是4.840。
BullFrog AI Holdings, Inc.股票的52周最低点是多少？
BullFrog AI Holdings, Inc.股票的52周最低点是0.804。
BullFrog AI Holdings, Inc.的市值是多少？
BullFrog AI Holdings, Inc.的市值是11.77M。
BullFrog AI Holdings, Inc.的净利润是多少？
BullFrog AI Holdings, Inc.的净利润为-7.04M。
现在BullFrog AI Holdings, Inc.(BFRG)的股票是买入、持有还是卖出？
根据分析师评级，BullFrog AI Holdings, Inc.(BFRG)的总体评级为--，目标价格为--。
BullFrog AI Holdings, Inc.(BFRG)股票的每股收益（EPS TTM）是多少
BullFrog AI Holdings, Inc.(BFRG)股票的每股收益（EPS TTM）是-0.687。
相关品种
